Jupiter Biomedical Research, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-21.
Jupiter Biomedical Research, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 21, 2026. The filing reports $30K sold. Its industry group is Biotechnology. It names Frank Gerardi (Executive Officer, Director), Richard Tambone (Executive Officer, Director), Robert Hackney (Executive Officer, Director) (SEC Form D, September 21, 2026).
In its own words: “Jupiter Biomedical Research is a preclinical, IND-enabling biotech advancing two patented oral small-molecule therapeutic candidates: JBR-102 for cancer (glioblastoma lead) and JBR-201 as a broad-spectrum antiviral.” (jupiterbiomedicalresearch.com, checked October 31, 2026)
Jupiter Biomedical Research, Inc. raised on Sep 21. 125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to Jupiter Biomedical Research, Inc.? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like Jupiter Biomedical Research, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-21 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Jupiter Biomedical Research, Inc.
Free to see. No signup.
More on the people and the money behind Jupiter Biomedical Research, Inc., from the filings we hold.
Biotechnology raises by companies based in Florida, filed within 90 days of this one, largest first.
Get an email when Jupiter Biomedical Research, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Jupiter Biomedical Research, Inc. raises, hires or launches. No email unless you switch it on.
Watch Jupiter Biomedical Research, Inc. →Get the full cited report on Jupiter Biomedical Research, Inc.
What the filing shows about Jupiter Biomedical Research, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Jupiter Biomedical Research, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Jupiter Biomedical Research, Inc.'s address as 3710 Buckeye Street, Ste. 100, Palm Beach Gardens, FL 33410.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Jupiter Biomedical Research, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Jupiter Biomedical Research, Inc. See pricing
Jupiter Biomedical Research, Inc. is a registered filer with the SEC (CIK 1694280) and has filed since 2025-07-29. 3 filings are on record, the latest on 2026-09-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Jupiter Biomedical Research, Inc.'s Form D of 2026-09-21 names Frank Gerardi, Richard Tambone, Robert Hackney and 3 more as its officers, directors or promoters.
Its new offerings report $251K sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $30K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Frank Gerardi is named as Executive Officer and Director on the Form D that Jupiter Biomedical Research, Inc. filed with the SEC on 21 September 2026, one of 6 people that filing names.
Richard Tambone is named as Executive Officer and Director on the Form D that Jupiter Biomedical Research, Inc. filed with the SEC on 21 September 2026, one of 6 people that filing names.
Robert Hackney is named as Executive Officer and Director on the Form D that Jupiter Biomedical Research, Inc. filed with the SEC on 21 September 2026, one of 6 people that filing names.
John Fanaras is named as Executive Officer and Director on the Form D that Jupiter Biomedical Research, Inc. filed with the SEC on 21 September 2026, one of 6 people that filing names.
Tipton Shonkwiler is named as Director on the Form D that Jupiter Biomedical Research, Inc. filed with the SEC on 21 September 2026, one of 6 people that filing names.
David Vaughan is named as Director on the Form D that Jupiter Biomedical Research, Inc. filed with the SEC on 21 September 2026, one of 6 people that filing names.
6 people named on the filing — 4 holding an executive role and 2 as directors only.
Named as of the 2026-09-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Jupiter Biomedical Research, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Jupiter Biomedical Research, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jupiter Biomedical Research, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Jupiter Biomedical Research, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Jupiter Biomedical Research, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-27 (jupiterbiomedicalresearch.com).
Each opens in a new tab, filled in for Jupiter Biomedical Research, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Miami raises, week of 2026-09-21 · Biotech raises, week of 2026-09-21 · Biotech raises in Miami
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/jupiter-biomedical-research-inc-form-d-001264